IL145800A0 - Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen - Google Patents

Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen

Info

Publication number
IL145800A0
IL145800A0 IL14580099A IL14580099A IL145800A0 IL 145800 A0 IL145800 A0 IL 145800A0 IL 14580099 A IL14580099 A IL 14580099A IL 14580099 A IL14580099 A IL 14580099A IL 145800 A0 IL145800 A0 IL 145800A0
Authority
IL
Israel
Prior art keywords
tumor
immunotheraphy
cancer
expression
associated antigen
Prior art date
Application number
IL14580099A
Other languages
English (en)
Inventor
Milcho S Mincheff
Dmitri I Loukinouv
Serguei Zoubak
Original Assignee
American Foundation For Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Foundation For Biolog filed Critical American Foundation For Biolog
Publication of IL145800A0 publication Critical patent/IL145800A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14580099A 1998-09-30 1999-09-09 Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen IL145800A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,034 US6387888B1 (en) 1998-09-30 1998-09-30 Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
PCT/US1999/020508 WO2000018933A1 (en) 1998-09-30 1999-09-09 Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen

Publications (1)

Publication Number Publication Date
IL145800A0 true IL145800A0 (en) 2002-07-25

Family

ID=22592693

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14580099A IL145800A0 (en) 1998-09-30 1999-09-09 Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen

Country Status (7)

Country Link
US (1) US6387888B1 (xx)
AU (1) AU5911999A (xx)
BG (1) BG106028A (xx)
CA (1) CA2368856A1 (xx)
IL (1) IL145800A0 (xx)
WO (1) WO2000018933A1 (xx)
ZA (1) ZA200108175B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US6897062B1 (en) * 1999-04-09 2005-05-24 Sloan-Kettering Institute For Cancer Research DNA encoding the prostate-specific membrane antigen-like gene and uses thereof
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
CA2424777A1 (en) * 2000-10-05 2003-04-01 Takeda Chemical Industries, Ltd. Novel protein, process for producing the same and use thereof
IL158184A0 (en) * 2001-03-30 2004-03-28 Univ California Anti-muc-1 single chain antibodies for tumor targeting
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
EP1507540A4 (en) * 2001-10-10 2006-12-06 Centocor Inc NUCLEIC ACID VACCINES USING NUCLEIC ACIDS ENCODING A TUMOR ANTIGEN AND A NUCLEIC ACID ENCODING A CYTOKINE ADJUVANT
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP1448588A4 (en) * 2001-10-23 2006-10-25 Psma Dev Company L L C ANTIBODIES AND MULTIMERS OF PSMA PROTEINS
WO2003073828A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
ITMN20020013A1 (it) 2002-04-04 2003-10-06 Amfag Spa Doccia estraibile da cucina
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
WO2004096238A1 (en) * 2003-04-01 2004-11-11 Centocor, Inc. Nucleic acid compositions and methods for use
WO2005000889A1 (en) * 2003-06-05 2005-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
JP2007202490A (ja) * 2006-02-02 2007-08-16 National Institute Of Advanced Industrial & Technology 動物細胞用新規発現ベクター
KR100896483B1 (ko) 2007-07-13 2009-05-08 연세대학교 산학협력단 Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물
WO2009046739A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US8565892B2 (en) * 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
JP5504510B2 (ja) * 2012-02-20 2014-05-28 独立行政法人産業技術総合研究所 動物細胞用新規発現ベクター
EP3536700A1 (en) 2012-06-07 2019-09-11 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
JP2019500025A (ja) * 2015-11-18 2019-01-10 オービス ヘルス ソリューションズ エルエルシー Ｔ７アルファウイルスベクター系

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861589A (en) 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US5013645A (en) 1987-04-14 1991-05-07 Abbott Laboratories Immunological methods and materials for detection of tumor associated antigens
US5660834A (en) 1988-03-11 1997-08-26 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5773215A (en) 1989-10-24 1998-06-30 Board Of Regents, The University Of Texas System Tumor marker protein for cancer risk assessment
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5227471A (en) 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
WO1993020185A1 (en) 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
EP0668777B2 (en) 1992-11-05 2011-02-09 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
DE69435010T2 (de) 1993-04-20 2008-04-30 Hipler Partners Llp Verfahren und stoffe für die behandlung von individuen, die infiziert sind mit intrazellulär infektiösen agentien
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
WO1995004548A1 (en) 1993-08-11 1995-02-16 Jenner Technologies Prostatic cancer vaccine
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
AR006250A1 (es) 1996-03-15 1999-08-11 Corixa Corp Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico

Also Published As

Publication number Publication date
WO2000018933A1 (en) 2000-04-06
US6387888B1 (en) 2002-05-14
ZA200108175B (en) 2003-01-06
AU5911999A (en) 2000-04-17
BG106028A (bg) 2002-12-29
CA2368856A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
IL145800A0 (en) Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen
IL131539A0 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
HUP0002095A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
IL140845A0 (en) Compositions for therapy and diagnosis of prostate cancer
EP1055684A4 (en) TUMORANTIGENS IN THE FORM OF PEPTIDE DERIVATIVES
GB2318734B (en) Methods of preventing breast cancer
AU2948199A (en) Breast cancer antigen
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
GB9804065D0 (en) Tumour associated antigen 791Tgp72
GB9703633D0 (en) Cancer therapy
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
SI1140147T1 (sl) Terapija s hcg za zdravljenje metastatskega raka na dojki
GB9819999D0 (en) Treatment of cancer
ZA981585B (en) Compounds for immunotherapy of prostate cancer and methods for their use
EP1107665A4 (en) METHOD FOR DIAGNOSING PROSTATE CANCER
ZA981536B (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
AUPO851597A0 (en) Treatment of prostate cancer
GB9624800D0 (en) Methods of preventing breast cancer
IL142311A0 (en) Methods and compositions for the diagnosis and therapy of prostate cancer
GB9721697D0 (en) Tumour antigen
AU6536898A (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
ZA972238B (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer.
SI1157041T1 (sl) Protitelesa za terapijo in diagnozo raka
AU8719298A (en) Treatment of prostate cancer